TEL AVIV, Israel, August 28, 2018 /PRNewswire/ --
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in
personalized cannabinoid medicine focused on cancer and its side
effects, Board of Directors is proud to announce its addition of Dr
Giloz-Ran, former manager of Grants Capital Investment, at INTEL
Corporation, Israel - to its
advisory board.
(Logo:
http://mma.prnewswire.com/media/485543/Cannabics_Logo.jpg )
"We are honored to have Dr. Giloz-Ran join our Board of
Advisors, her exceptional record in international business
management suits us well as our state-of-the-art laboratory comes
into operation and we are being approached by potential medical
partners to explore joint ventures," said Eyal Ballan, CTO.
Estery Giloz-Ran is a PhD and CPA who has over a decade
specializing in multi-national business development. Dr Gilon-Raz
served as head of grants capital investment law, at INTEL
Corporation, Israel. She is past
Chairman of the Board of Tamir
Fishman, a venture capital firm; has been external director
in eight significant public companies such as KAMADA (NASDAQ:
KMDA); Director at Emerald, a medical device company; lecturer at
Bar Ilan University, Ben Gurion University; and visiting professor at
the Stern Business School (New
York).
"I'm excited to join CNBX's outstanding vision," says Dr
Gilon-Raz. "The need for a natural cancer cure is a well-known fact
and I'm happy to help the company reaching that goal, using new
collaborations with leading global players."
Dr. Giloz-Ran received her CPA as a certified public accountant
in 2007; MBA (cum laude) from Ben Gurion
University in 2010, PhD in accounting and finance from
Ben Gurion University (2013), and did
her postdoctoral work at New York
University in 2014.
Dr. Giloz-Ran joins the current Board of Advisors which includes
Dr. Gil Feiler, Business
Development, Scientific Advisor; Prof. Amos
Toren, MD, Medical Advisor; Dr. Tal
Mofkadi, financial advisor, and Dr. Sigalit Ariely- Portnoy, Strategic Regulatory
Advisor, Clinical, Quality and Validation.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a United States
public company that is developing a platform that leverages drug
screening and artificial intelligence to develop cannabinoid-based
therapies for palliative care and cancer treatments that are more
precise to a patient's profile and specific cancer. By developing
tools to assess effectiveness on a personalized basis, Cannabics is
helping to move medical cannabinoids into the future of cancer
therapies. The company's R&D is based in Israel, where it
is licensed by the Health Ministry to conduct scientific and
clinical research on cannabinoid formulations. For more
information, please visit http://www.cannabics.com or contact
us at Info@Cannabics.com
Disclaimer:
Certain statements contained in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives, the
effect of any competitive products, our ability to license and
protect our intellectual property, our ability to raise additional
capital in the future that is necessary to maintain our business,
changes in government policy and/or regulation, potential
litigation by or against us, any governmental review of our
products or practices, as well as other risks discussed from time
to time in our filings with the Securities and Exchange Commission,
including, without limitation, Cannabics Pharmaceuticals' latest
10-Q Report filed on July 16th, 2018. We undertake
no duty to update any forward-looking statement or any information
contained in this press release or in other public disclosures at
any time. Finally, the investing public is reminded that the only
announcements or information about Cannabics Pharmaceuticals Inc.
which are condoned by the Company must emanate from the Company
itself, and bear our name as its Source.
Media Contact
Liz Crumpacker
cannabics@Antennagroup.com
+1-877-424-2429
SOURCE Cannabics Pharmaceuticals Inc.